On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a deal that could eventually be worth up to $2.1 billion. For a company still years away from selling anything, a check like that changes the math.
A Pipeline Firing On Multiple Fronts
The newly launched study will track participants for as long as a year of treatment with MRT-6160, comparing it against placebo across multiple sites, to pick the right dose before a Phase 3 program begins. Novartis is footing the entire bill for that work, and Monte Rosa stands to collect further payments each time a new Phase 2 study opens for MRT-6160 in other immune conditions. That arrangement lets the drug keep moving forward without touching Monte Rosa’s own cash.
The molecule already has clinical evidence behind it: in an earlier Phase 1 trial, it knocked down VAV1 protein levels by over 90% in patients’ T cells and calmed key markers of inflammation, without triggering any serious side effects. Sjögren’s disease itself is a large, often invisible target, striking about a quarter of one percent of the population and going undiagnosed in roughly half of those who have it, which leaves plenty of room for a treatment to find patients once approved. The VAV1 asset isn’t carrying the company alone.
On August 6, Monte Rosa reported that enrollment and dosing had wrapped up in its GFORCE-1 study of MRT-8102 in people with elevated cardiovascular risk, with results due later in 2026, building on earlier findings of an 85% median drop in CRP after just four weeks of treatment. The company also got its MODeFIRe-1 study up and running, pairing MRT-2359 with the prostate cancer drug apalutamide in patients whose tumors carry androgen receptor mutations. Backing all of this is $626 million in cash, equivalents, and marketable securities as of June 30, which management says can fund operations into 2029.
The Losses Keep Growing
None of that progress has come cheap. Revenue from Monte Rosa’s collaborations dropped to $9.0 million in the second quarter of 2026 from $23.2 million a year earlier, while research spending rose to $48.0 million from $30.7 million and administrative costs climbed to $10.1 million from $8.1 million. Put together, the quarterly net loss ballooned to $43.4 million, more than triple the $12.3 million loss from the same period in 2025.
Milestone checks like the one tied to Sjögren’s help plug that gap, but they arrive on Novartis’s schedule, not Monte Rosa’s, and there’s no guarantee the pace continues. Every program described above, whether it’s the VAV1 collaboration, the NEK7-targeted MRT-8102, or the CDK2 and cyclin E1 efforts still working toward a future IND filing, remains in mid-stage testing at best. There’s no approved product on the market yet, and Phase 2 success is no guarantee that any of these drugs eventually clear Phase 3 and reach patients.
Wall Street Can’t Quite Agree
Hedge fund ownership of Monte Rosa edged up to 36 funds from 35 the prior quarter, a small sign of growing institutional interest. Short sellers disagree, with 21.52% of the float sold short, a level that points to a genuine bear camp betting against the stock. Rising fund ownership alongside that much short interest is an unusual pairing, and it suggests the market hasn’t settled on whether the milestone cash flow outweighs the widening losses.
The Milestones Still Ahead
Monte Rosa’s next stretch depends heavily on progress it can’t fully control. Novartis needs to keep pushing MRT-6160 through the studies that unlock more of that $2.1 billion in potential milestones, while Monte Rosa’s own MRT-8102 and MRT-2359 programs need their upcoming data to hold up. Positive results across those trials, paired with cash that management says lasts into 2029, would give the company real runway to reach later-stage, more definitive results.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
